Literature DB >> 3475676

Concurrent mutations in two different ras genes in acute myelocytic leukemias.

J W Janssen, J Lyons, A C Steenvoorden, H Seliger, C R Bartram.   

Abstract

DNA transfection analyses (tumorigenicity assay) and hybridization to mutation specific oligonucleotide probes established point mutations in codon 61 of both, N-ras and Ki-ras genes in fresh leukemic cells of an AML patient. Concurrent activation of N-ras and Ki-ras sequences by point mutations in codons 12 were demonstrated for AML cell line Rc2a. Moreover, using a rapid and sensitive dot-blot screening procedure based on the combination of in vitro amplification of ras specific sequences and oligonucleotide hybridization we could show that ras gene activation was not present in primary leukemic cells of the patient this cell line had been derived from, but rather occurred during later passages of Rc2a.

Entities:  

Mesh:

Year:  1987        PMID: 3475676      PMCID: PMC306014          DOI: 10.1093/nar/15.14.5669

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  34 in total

1.  Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.

Authors:  J B Gibbs; I S Sigal; M Poe; E M Scolnick
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

2.  Structure and activation of the human N-ras gene.

Authors:  E Taparowsky; K Shimizu; M Goldfarb; M Wigler
Journal:  Cell       Date:  1983-09       Impact factor: 41.582

3.  New human transforming genes detected by a tumorigenicity assay.

Authors:  O Fasano; D Birnbaum; L Edlund; J Fogh; M Wigler
Journal:  Mol Cell Biol       Date:  1984-09       Impact factor: 4.272

4.  Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene.

Authors:  J P McGrath; D J Capon; D H Smith; E Y Chen; P H Seeburg; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1983 Aug 11-17       Impact factor: 49.962

Review 5.  The molecular genetics of cellular oncogenes.

Authors:  H E Varmus
Journal:  Annu Rev Genet       Date:  1984       Impact factor: 16.830

6.  Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient.

Authors:  T Sekiya; M Fushimi; H Hori; S Hirohashi; S Nishimura; T Sugimura
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

7.  Comparative biochemical properties of normal and activated human ras p21 protein.

Authors:  J P McGrath; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

8.  Oncogene activation in human myeloid leukemia.

Authors:  J W Janssen; A C Steenvoorden; J G Collard; R Nusse
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

9.  Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization.

Authors:  J L Bos; M Verlaan-de Vries; A M Jansen; G H Veeneman; J H van Boom; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1984-12-11       Impact factor: 16.971

10.  A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer.

Authors:  Y Taya; K Hosogai; S Hirohashi; Y Shimosato; R Tsuchiya; N Tsuchida; M Fushimi; T Sekiya; S Nishimura
Journal:  EMBO J       Date:  1984-12-01       Impact factor: 11.598

View more
  10 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

2.  Transforming genes and chromosome aberrations in therapy-related leukemia and myelodysplastic syndrome.

Authors:  K Inokuchi; N Amuro; M Futaki; K Dan; T Shinohara; S Kuriya; T Okazaki; T Nomura
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

3.  Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase.

Authors:  M C McGuire; C P Nogueira; C F Bartels; H Lightstone; A Hajra; A F Van der Spek; O Lockridge; B N La Du
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 4.  The polymerase chain reaction: an improved method for the analysis of nucleic acids.

Authors:  H P Vosberg
Journal:  Hum Genet       Date:  1989-08       Impact factor: 4.132

5.  Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing.

Authors:  S M Grimmond; D Raghavan; P J Russell
Journal:  Urol Res       Date:  1992

6.  Analysis of RAS oncogene mutations in human lymphoid malignancies.

Authors:  A Neri; D M Knowles; A Greco; F McCormick; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Authors:  Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross L Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc M Loriaux
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

8.  Concomitant K- and N-ras gene point mutations in clonal murine lymphoma.

Authors:  L E Diamond; I Guerrero; A Pellicer
Journal:  Mol Cell Biol       Date:  1988-05       Impact factor: 4.272

9.  Incidence of ras gene mutations in neuroblastoma.

Authors:  K Ballas; J Lyons; J W Janssen; C R Bartram
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

10.  RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

Authors:  J W Janssen; A C Steenvoorden; J Lyons; B Anger; J U Böhlke; J L Bos; H Seliger; C R Bartram
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.